Abstract:Background Port wine birthmark (PWB) is a congenital vascular malformation of the skin. Pulsed dye laser (PDL) is the "gold standard" for the treatment of PWB globally. Hematoporphyrin monomethyl ether (HMME or hemoporfin)‐mediated photodynamic therapy (HMME–PDT) has emerged as the first choice for PWB treatment, particularly for young children, in many major hospitals in China during the past several decades. Aim To evaluate whether HMME–PDT is superior to PDL by comparing the clinical efficacies of both modalities. Method PubMed records were searched for all relevant studies of PWB treatment using PDL (1988−2023) or HMME–PDT (2007−2023). Patient characteristics and clinical efficacies were extracted. Studies with a quartile percentage clearance or similar scale were included. A mean color clearance index (CI) per study was calculated and compared among groups. An overall CI (C0), with data weighted by cohort size, was used to evaluate the final efficacy for each modality. Result A total of 18 HMME–PDT studies with 3910 patients in China were eligible for inclusion in this analysis. Similarly, 40 PDL studies with 5094 patients from nine different countries were eligible for inclusion in this analysis. Over 58% of patients in the HMME‐PDT studies were minors (<18 years old). A significant portion (21.3%) were young children (<3 years old). Similarly, 33.2% of patients in the PDL studies were minors. A small proportion (9.3%) was young children. The overall clearance rates for PDL were slightly, but not significantly, higher than those for HMME–PDT in cohorts with patients of all ages (C0, 0.54 vs. 0.48, p = 0.733), subpopulations with only minors (C0, 0.54 vs. 0.46, p = 0.714), and young children (C0, 0.67 vs. 0.50, p = 0.081). Regrettably, there was a lack of long‐term data on follow‐up evaluations for efficacy and impact of HMME‐PDT on young children in general, and central nervous system development in particular, because their blood‐brain barriers have a greater permeability as compared to adults. Conclusion PDL shows overall albeit insignificantly higher clearance rates than HMME‐PDT in patients of all ages; particularly statistical significance is nearly achieved in young children. Collectively, current evidence is insufficient to support HMME–PDT as the first choice of treatment of PWBs in young children given: (1) overall inferior efficacy as compared to PDL; (2) risk of off‐target exposure to meningeal vasculature during the procedure; (3) administration of steriods for mitigation of side effects; ‐and (4) lack of long‐term data on the potential impact of HMME on central nervous system development in young children.

Early history of clinical application of photosensitizing drugs in photodynamic therapy (PDT) of portwine stain (PWS) birthmarks

Advances in Photodynamic Therapy for Port-Wine Stain and Our Experience

Recent progress in hematoporphyrin monomethyl ether-photodynamic therapy for port-wine stains: updates and insights

Hemoporfin-mediated photodynamic therapy on normal vasculature: implications for phototherapy of port-wine stain birthmarks.

Efficacy and influential factors of hematoporphyrin monomethyl ether mediated photodynamic therapy in the treatment for port-wine stains

Research Progress of Photodynamic Therapy for Port-Wine Stain

Efficacy of photodynamic therapy in the treatment of port wine stains: A systematic review and meta-analysis

Comparison of Two Generation Photosensitizers of PsD-007 and Hematoporphyrin Monomethyl Ether Photodynamic Therapy for Treatment of Port-Wine Stain: A Retrospective Study.

Experimental study of combined photodynamic and photothermal therapy in the treatment of port wine stain

18 Years Long-Term Results of Facial Port-Wine Stain (pws) after Photodynamic Therapy (pdt) - A Case Report

478 Comparison of Two Generation Photosensitizers of PsD-007 and HMME Photodynamic Therapy for Treatment of Port-Wine Stain: A Retrospective Study

Evaluation of Efficacy of Hemoporfin-PDT in the Treatment of PWS Birthmarks of Young Children Previously Received PDL Treatment

Non-invasive efficacy assessment of pulsed dye laser and photodynamic therapy for port-wine stain

Safety and Efficacy of Dual-Wavelength Laser (1064 + 595 Nm) for Treatment of Non-Treated Port-Wine Stains.

Current clinical evidence is insufficient to support HMME–PDT as the first choice of treatment for young children with port wine birthmarks

Histological Characteristics of Port-Wine Stains with Complete Regression After Photodynamic Therapy Treatment: A 7-Year Follow-Up

Hemoporfin-mediated photodynamic therapy for the treatment of port-wine stain: A multicenter, retrospective study

Hematoporphyrin monomethyl ether photodynamic therapy for the treatment of Sturge–Weber syndrome and large segmental facial port‐wine stain

Efficacy and Safety of Hemoporfin in Photodynamic Therapy for Port-Wine Stain: A Multicenter and Open-Labeled Phase Iia Study

Treatment of Port-Wine Stains with the 595-Nm Pulsed Dye Laser: A Pilot Study in Chinese Patients

Influential Factors in the Efficacy of Hemoporfin-Mediated Photodynamic Therapy for Port-wine Stains.